Looking for Research Participants

‍

PARTICIPATION

1 initial meeting, approximately 30 – 60 mins

1 - 2 interviews, approximately 60 mins each

‍

LOCATION

Zoom

‍

ELIGIBILITY

Individuals over 18 years old who have undergone psychedelic-assisted therapy by care practitioners* in Canada within the last 20 years

and / or

Care practitioners* who currently provide OR have provided psychedelic-assisted therapy in Canada within the last 20 years

*Care practitioner includes individuals with formal & informal training or mentorship

‍

CONTACT

Interested in participating or learning more?

Please contact:

Michelle Gagnon, PhD candidate

Email: michelle.r.gagnon@ubc.ca

Study Contact

or

Dr. Vicky Bungay, PhD

Email: vicky.bungay@ubc.ca

Primary Investigator

‍

Help us grow our knowledge base of psychedelic-assisted therapy in Canada by sharing your experiences

Did you participate in the MAPS-sponsored MDMA-assisted therapy for PTSD clinical trials? If so, this follow-up study might be for you.

We ’re looking for Phase 3 participants who completed the clinical trials to explore their bodily experience of this treatment.

Many guidebooks for psychedelic-assisted therapy as well as the MAPS Manual for MDMA-assisted therapy for PTSD mention the use of body-based approaches in this therapy. As MDMA-assisted therapy for PTSD may become legal for wider use in the near future, this research seeks to better understand the role of body-based interventions in this approach, and the possible role of the body in the resolution of trauma.

Participants in the current study will be asked to complete:

• A screening process through email to ensure inclusion criteria are met
• A two-hour video call with the lead researcher to complete the interview

Upon completion, participants will receive:

• $10 Starbucks gift card as compensation for their time
• An entry into a draw for a $50 Amazon gift card

Location: Virtual

If you ’re interested in participating or want to learn more about the study, please contact the study lead:

Stephanie Kale, Registered Psychotherapist (PhD Candidate)

School of Counselling, Psychotherapy, and Spirituality

Saint Paul University, Ottawa, Canada

SKale017@uottawa.ca  

Interested about the therapeutic benefits of psychedelics, fluent in English, and at least 18 years old? Then check out this new study on the relationship between Psychedelic use, Insight and Psychological Well-being. To take the survey, please visit the link below:

https://utorontopsych.az1.qualtrics.com/jfe/form/SV_d5v1z0AaBfMEUGq

This survey is completely anonymous, does not collect any personally identifying information (e.g., name, IP address), and takes approximately 15-30 minutes to complete. You will also be able to enter a draw to win one of twenty Amazon gift cards valued at $25 CAD.

If you have any questions or concerns, please email: insight.wellbeing.study@gmail.com

Thank you!

‍

If you are a registered psychologist or a student in a graduate clinical or counselling psychology program in Canada, you are invited to participate in an online survey.

Psychologists and psychology trainees perceptions of therapies are critical for future implementation, and attitudes towards psychedelics and psychedelic therapy have seldomly been addressed in the literature, especially in Canada. This addition to the limited literature on the perceptions of psychedelics in Canada will contribute to the field by elucidating potential barriers for acceptance and use of psychedelic therapy.

To participate please click on the survey link: https://uleth.qualtrics.com/jfe/form/SV_1zBRXXqzejAiBdY

There is a new online study researching the effects of psilocybin on consciousness.

This study has been reviewed and approved by Western University’s Research Ethics Board, and it is meant to investigate how psilocybin influences the experience of visual illusions, as well as cognitive performance on various tests (e.g. memory, reasoning, etc.).

Participation is entirely online, and individuals can perform the tests – a series of computer games and visual tasks – from the comfort of their home.

By looking at visual processing and cognition, we hope to enhance our understanding of psilocybin’s varying effects on consciousness.

For more information or to take part, please visit:
tinyurl.com/uwo-psilocybin

‍

We are a group of researchers at the Centre for Addiction and Mental Health (CAMH) and University of Toronto, Toronto, Canada, doing a study, titled Knowledge, Perceptions, and Use of Psychedelics among intellectually able adults with autism spectrum condition: An online survey. 

We are doing this project to learn about the perception, opinions, and knowledge of autistic adults about psychedelics, and whether they have used them in the past. Psychedelic compounds are a group of chemicals that change or enhance sensory perceptions, thought processes, and energy levels. These compounds are sometimes used to facilitate spiritual experiences. Psychedelic compounds have shown impressive effects in neurotypical people with depression, post-traumatic stress disorder, substance misuse, and obsessive compulsive disorder, etc. Many clinical trials of psychedelics have been published in neurotypical populations and many more are ongoing. Nonetheless, there has been only one clinical trial of 3,4-Methyl​enedioxy​methamphetamine (MDMA), one of psychedelics) in autistic adults with co-occurring social anxiety disorder. This neglect represents mental health and research inequity. Therefore, we want to do this study to listen to voices from autistic people to guide research and practice priorities surrounding the possible future uses of psychedelics. 

The survey should take between 20 to 30 minutes to complete.  Any information we collect from people is private and deciding to complete the survey is voluntary. Completing the survey (or not) will not impact the care anyone receives at their medical service providers (including CAMH) now or in the future.

Numinus Wellness Inc.  is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study.

The study in Draper, Utah, is a part of COMPASS Pathway's phase 3 program in TRD. The international program is composed of two pivotal trials, each with a long-term follow-up component. It will enroll over 800 participants, with topline data expected in summer 2024 and mid-2025.

The launch of the phase 3 program follows positive results from COMPASS Pathways' phase 2b trial, published in the New England Journal of Medicine, the world's leading peer-reviewed medical journal. The objective of the randomized, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3.

"COMPASS is helping to lead the way in psilocybin research and development for treatment-resistant depression," said Dr. Paul Thielking, Chief Science Officer at Numinus. "We are very proud of the work we are doing alongside COMPASS to elevate the industry and contribute to the growing body of research."

Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: "Tens of millions of people around the world suffer with depression that doesn't respond to traditional treatments. The results from our phase 2b study of investigational COMP360 psilocybin therapy were very encouraging, and we hope that the data from our pivotal phase 3 program will form the basis for our submission to regulatory bodies. We're grateful to all the people involved in our phase 3 program around the world. It is a significant milestone in our journey to make COMP360 psilocybin therapy available to patients, and towards building a better future for mental health care."

People who are interested in taking part in the study should go to https://compasspathfinderstudies.com/  or https://numinus.com/clinical-trials/psychedelics/#!/study/28  to understand if they might be eligible to join.

THE LOVE PROJECT: SEEKING VOLUNTEERS FOR A SURVEY STUDY ON LOVE & PSYCHEDELICS

‍
If you are 21 or older and fluent in English, we invite you to participate in The Love Project research, which involves a 30 minute survey to explore the nature of love in the context of a psychedelic experience. These questions seek your opinions and experience about a profound personal experience of love with psychedelics, as well as your perspective on the role of love in healing in the setting of professional care more broadly.
‍

We hope that in addition to supporting a scientific understanding of love, your participation in this study can also serve as a contemplative opportunity for you. Taking
time to reflect on the quality, process and impact of experiences of love can potentially deepen your their effects and orient you towards further integration.

More Information
https://psychedeliclove.org/survey-study

‍
THIS STUDY HAS BEEN APPROVED BY THE WILFRID LAURIER RESEARCH ETHICS BOARD #8282

‍

A new study has just been launched for all Canadians receiving psilocybin Section 56 Exemptions to advance psychedelic science by sharing their experiences, in a series of online questionnaires before and after the planned psilocybin session(s). This project brings together patients, community practitioners, and academic scientists across Canada and at Imperial College’s Center for Research Center in London, UK. It aims is to capture some of the first real-world safety and efficacy data of psychedelic therapy at this important moment in history.

Any questions can be direct to Dr. Kyle Greenway at McGill University: kyle.greenway@mail.mcgill.ca